Vincerx Pharma, Inc. Common Stock Asset Resilience Ratio
Vincerx Pharma, Inc. Common Stock asset resilience ratio. Vincerx Pharma, Inc. Common Stock (VINC) has an Asset Resilience Ratio of 47.80% as of September 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Vincerx Pharma, Inc. Common Stock fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Vincerx Pharma, Inc. Common Stock (2021–2023)
Asset resilience ratio of Vincerx Pharma, Inc. Common Stock from 2021 to 2023. This chart shows how Vincerx Pharma, Inc. Common Stock's Asset Resilience Ratio has changed over time. Read VINC liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Vincerx Pharma, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see VINC current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $7.14 Million | 47.8% |
| Total Liquid Assets | $7.14 Million | 47.80% |
Asset Resilience Insights
- Very High Liquidity: Vincerx Pharma, Inc. Common Stock maintains exceptional liquid asset reserves at 47.80% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Vincerx Pharma, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Vincerx Pharma, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
Vincerx Pharma, Inc. Common Stock Asset Resilience Ratio by Year (2021–2023)
Vincerx Pharma, Inc. Common Stock asset resilience ratio by year from 2021 to 2023. The table below shows the annual Asset Resilience Ratio data for Vincerx Pharma, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | $0.00 | $18.22 Million | -- |
| 2022-12-31 | 68.81% | $40.80 Million | $59.29 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $117.68 Million | -- |
About Vincerx Pharma, Inc. Common Stock
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops differentiated and novel therapies to address the unmet medical needs of patients with cancer in the United States. Its VersAptx bioconjugation platform combines different targeting, linker, and payload technologies to develop antibody-drug conjugates (ADC) and small molecule drug conjugates (SMDC); and prov… Read more